NeuX Capital

Atantares is a biotechnology company that leverages semiconductor technology to advance biomedicine through innovative microfluidics solutions. By utilizing the miniaturization and integration capabilities of silicon chips, the company develops precision medicines and smart diagnostic devices aimed at transforming disease management in hematology, cardiology, neurology, and oncology. Atantares offers a proprietary coagulation device designed to monitor specific drugs and blood products, employing coagulation assays that assess platelet function, clotting times, and viscoelasticity. Furthermore, the company focuses on creating a chimeric antigen receptor for the treatment of hematological tumors and various diseases, utilizing an ultrasensitive immunoassay platform to provide crucial cytokine profile data for the effective management of CAR T-cell therapy and cytokine release syndrome mitigation.

Degron Therapeutics is a drug discovery company focused on developing a new class of therapeutics centered around targeted protein degradation. The company specializes in molecular glue degrader drugs, which are small molecules designed to selectively target and degrade specific proteins associated with various diseases. Degron Therapeutics aims to lead the field of small molecule molecular glue degrader medicines by leveraging its expertise to identify and validate challenging disease targets that traditional small molecule inhibitors cannot effectively address. The company is committed to addressing unmet medical needs across a broad range of therapeutic areas by developing innovative protein degradation drugs, utilizing its advanced molecular glue platform technology to enhance treatment efficacy.

Metanovas Biotech develops health products using revolutionary AI technology. Its product pipeline includes pharmaceuticals, nutritional supplements, functional foods, and cosmetics, aiming to provide patients and consumers with better goods.